Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.
Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.
What I am trying to establish is how much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly. Practical detail welcome, however dull — the duller the better.
Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.